RT Journal Article
T1 Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases
A1 Buendia, Izaskun
A1 Michalska Dziama, Patrycja
A1 Navarro González De Mesa, Elisa
A1 Gameiro, Isabel
A1 Egea, Javier
A1 León Martínez, Rafael
AB Neurodegenerative diseases (NDDs) are predicted to be the biggest health concern in this century and the second leading cause of death by 2050. The main risk factor of these diseases is aging, and as the aging population in Western societies is increasing, the prevalence of these diseases is augmenting exponentially. Despite the great efforts to find a cure, current treatments remain ineffective or have low efficacy. Increasing lines of evidence point to exacerbated oxidative stress, mitochondrial dysfunction and chronic neuroinflammation as common pathological mechanisms underlying neurodegeneration. We will address the role of the nuclear factor E2-related factor 2 (Nrf2) as a potential target for the treatment of NDDs. The Nrf2–ARE pathway is an intrinsic mechanism of defence against oxidative stress. Nrf2 is a transcription factor that induces the expression of a great number of cytoprotective and detoxificant genes. There are many evidences that highlight the protective role of the Nrf2–ARE pathway in neurodegenerative conditions, as it reduces oxidative stress and neuroinflammation. Therefore, the Nrf2 pathway is being increasingly considered a therapeutic target for NDDs. Herein we will review the deregulation of the Nrf2 pathway in different NDDs and the recent studies with Nrf2 inducers as “proof-of-concept” for the treatment of those devastating pathologies.
SN 0163-7258
YR 2016
FD 2016-01-01
LK https://hdl.handle.net/20.500.14352/95760
UL https://hdl.handle.net/20.500.14352/95760
LA eng
NO Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, León R. Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacology & Therapeutics 2016;157:84–104. https://doi.org/10.1016/j.pharmthera.2015.11.003.
NO Fundación Teófilo Hernando
NO European Commission
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 21 jul 2024